313402-16-3

Usage

Uses

Used in Pharmaceutical Research and Development:
3-(1H-Benzoimidazol-2-yl)-4-chloro-phenylamine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to serve as a building block for the development of new drugs with potential applications in treating a range of diseases.
Used in Cancer Therapy:
In the field of oncology, 3-(1H-Benzoimidazol-2-yl)-4-chloro-phenylamine is used as a potential anti-cancer agent. Its ability to target and inhibit specific enzymes and pathways involved in cancer cell growth and proliferation makes it a promising candidate for the development of novel cancer therapies.
Used in Enzyme Inhibition:
3-(1H-Benzoimidazol-2-yl)-4-chloro-phenylamine is employed as an enzyme inhibitor in various biological and medicinal applications. Its capacity to modulate enzyme activity can be leveraged to develop treatments for conditions where enzyme dysregulation plays a significant role in disease progression.
Used in Neurological Disorder Treatment:
3-(1H-Benzoimidazol-2-yl)-4-chloro-phenylamine has been investigated for its potential use in treating neurological disorders. Its pharmacological properties may offer new avenues for the development of therapies targeting conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Used in Laboratory Research:
In the realm of scientific research, 3-(1H-Benzoimidazol-2-yl)-4-chloro-phenylamine serves as a valuable tool for studying the mechanisms of action of various biological processes. Its use in laboratory settings aids researchers in understanding the molecular underpinnings of diseases and in the discovery of new therapeutic targets.

InChI:InChI=1/C13H10ClN3/c14-10-6-5-8(15)7-9(10)13-16-11-3-1-2-4-12(11)17-13/h1-7H,15H2,(H,16,17)

Upstream product

• 349406-06-0 2-chloro-5-nitro-N-(2-nitrophenyl)benzamide 
• 95-54-5 1,2-diamino-benzene 
• 54255-74-2 N-(2-aminophenyl)-2-chloro-5-nitrobenzamide 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 25784-91-2 2-chloro-5-nitrobenzoylchloride 
• 54255-79-7 2-(2-chloro-5-nitrophenyl)-1H-benzo[d]imidazole 

Downstream Products

• 1185108-74-0 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-4-(dimethylamino)benzamide 
• 1185108-84-2 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-4-fluorobenzamide 
• 1185108-78-4 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-4-cyanobenzamide 
• 1185108-89-7 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-3-(trifluoromethyl)benzamide 
• 496793-78-3 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-3,4,5-trimethoxybenzamide 
• 420828-12-2 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-benzamide 
• 1184871-66-6 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-4-chlorobenzamide 
• 420826-66-0 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-4-methoxybenzamide 
• 496794-60-6 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-2-methoxybenzamide 

Relevant academic research and scientific papers

Preparation method and application of antibacterial drugs

The invention provides phosphite ester compounds with an antibacterial effect and represented by a general formula I, a preparation method of the compounds, an application of the compounds in antibacterial drugs and pharmaceutical compositions containing the compounds. The ten synthesized compounds are novel in structure, the antibacterial activity of the compounds is equivalent to or even superior to that of positive control clindamycin and ciprofloxacin, the antibacterial spectrum is wide, and the compounds 5 and 10 are particularly expected to be further developed into antibacterial activedrugs.

Comprising benzimidazole structure of sulfonamide derivatives and its preparation and use

The invention belongs to the field of medical technology, discloses benzimidazole structure of sulfonamide derivatives and its preparation method and application. The derivatives of formula I as shown in the structural formula, in formula I, R1 , R2 , R3 , R4 , X such as the claim and the specification. The compounds of the invention has better anti-tumor activity, can be used as a therapeutic agent for the treatment of tumor, it is also SMO inhibitors. (Type I).

N - 3 - benzimidazole thiazole derivative and its preparation method and application

The invention discloses a new compound N-3-benzimidazole thiazole amine derivative and a preparation method and application thereof. A structural formula of the compound is shown as in figure I, and in the figure I, R1 is morpholinyl, piperidyl, N-methyl piperazinyl, N-arylpiperazine, diethylin, ethyoxyl, (dimethoxy)ethylamino, or R1 is one of mono-substituted or multi-substituted aniline on the following benzene ring: fluorine, chlorine, trifluoromethoxyl, methyl, methoxyl, hydroxyl group, nitryl, amino group, acetamido, trifluoromethyl and cyano group. The compound disclosed by the invention has better antineoplastic activity, and can be used as a therapeutic agent for treating a tumor in the field of antineoplastic drug preparation.

Nicotinamide derivative and preparation method and application thereof

The invention discloses a novel compound N-3-(4-R2 substituted)-(1-R-substituted benzimidazole)-(1'-R3 substituted)-2'-oxa-nicotinamide derivative, and a preparation method and an application thereof.The structural formula of the compound is as shown in a formula I, in which R1, R2 and R3 are described in the claims and description. The compound has very good anti-diabetes activity, and can be used as therapeutic agent for treating diabetes in the field of preparing anti-diabetes drugs. The formula is as shown in the description.

A second group of the benzimidazole aryl amide compound and its synthesis and use

The invention relates to a diaryl amide compound containing benzimidazole group as well as the synthesis and application of the diaryl amide compound and belongs to the field of chemical medicine. The compound has a general formula I shown in the specific

Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists

A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet. 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-arylpropanamide 65 was identified as the most potent, with an IC50 value of 9.53 nM against the Hh signaling pathway. Complementary mechanism studies confirmed that 65 inhibits Hh signaling pathway by targeting Smo and shares the same binding site as that of the tool drug cyclopamine. Meanwhile, 65 has a good plasma exposure and an acceptable oral bioavailability. Dose-dependent antiproliferative effects were observed in ptch+/-;p53-/- medulloblastoma cells, and significant tumor growth inhibitions were achieved for 65 in the ptch+/-;p53-/- medulloblastoma allograft model.

Synthesis and evaluation of novel N-3-benzimidazolephenylbisamide derivatives for antiproliferative and Hedgehog pathway inhibitory activity

A series of novel N-3-benzimidazolephenylbisamide derivatives bearing the 4-benzyloxyphenyl moiety were synthesized and evaluated for their antiproliferative activity against MGC803, HT29, MKN45 and SW620 cancer cell lines in vitro. The pharmacological data demonstrated that the majority of the target compounds exhibited higher efficacy against MGC803, HT29 and MKN45 cells, among which compound 7m displayed higher antiproliferative activity than vismodegib. Furthermore, compound 7m manifested better inhibition of the Hedgehog (Hh) signaling pathway in different Hh-related assays and may compete with boron-dipyrromethene (BODIPY)-cyclopamine for binding to the human smoothened (Smo) receptor. In addition, molecular docking studies suggested that compound 7m interacts very closely with the vismodegib docking pose through hydrogen bonds at the taladegib binding site of the Smo receptor.

HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The com-pounds can be used in methods of treating proliferative dis-eases and disorders such as cancer

Synthesis and biological evaluation of SANT-2 and analogues as inhibitors of the hedgehog signaling pathway

Hedgehog (Hh) signaling plays an important role in cell signaling of embryonic development and adult tissue homeostasis. In vertebrates, the hh gene encodes three different unique proteins: sonic hedgehog (Shh), desert hedgehog (Dhh) and indian hedgehog (Ihh). Disruption of the Hh signaling pathway leads to severe disorders in the development of vertebrates whereas aberrant activation of the Hh pathway has been associated with several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers. In vivo evidence suggests the antagonism of excessive Hh signaling provides a route to unique mechanism-based anti-cancer therapies. Recently the small molecule SANT-2 was identified as a potent antagonist of Hh-signaling pathway. Here, we describe the synthesis, SAR studies as well as biological evaluation of SANT-2 and its analogues. Fifteen SANT-2 derivatives were synthesized and analyzed for their interference with the expression of the Hh target gene Gli1 in a reporter gene assay. By comparison of structure and activity important molecular descriptors for Gli inhibition could be identified. Furthermore we identified derivative TC-132 that was slightly more potent than the parent compound SANT-2. Selected compounds were tested for Hh related teratogenic effects in the small teleost model medaka. Albeit Gli expression has indicated a 16-fold higher Hh-inhibiting activity than observed for the plant alkaloid cyclopamine, none of the tested compounds were able to induce the cyclopamine-specific phenotype in the medaka assay.

GDC-0449-A potent inhibitor of the hedgehog pathway

SAR for a wide variety of heterocyclic replacements for a benzimidazole led to the discovery of functionalized 2-pyridyl amides as novel inhibitors of the hedgehog pathway. The 2-pyridyl amides were optimized for potency, PK, and drug-like properties by modifications to the amide portion of the molecule resulting in 31 (GDC-0449). Amide 31 produced complete tumor regression at doses as low as 12.5 mg/kg BID in a medulloblastoma allograft mouse model that is wholly dependent on the Hh pathway for growth and is currently in human clinical trials, where it is initially being evaluated for the treatment of BCC.